N/A N=106 Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia
Social Phobia
Primary: Social Phobia Remission
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=169 D-Cycloserine Enhancement of Exposure in Social Phobia
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 39.19; 42.44 units on a scale
N/A N=48 Attention Disengagement Training for Social Phobia
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 68.1; 74.5; 60.0; 46.1 units on a scale
Phase 3 N=169 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
Social Anxiety Disorder
Primary: Social Phobic Disorders Severity and Change Form — 2.68; 2.95 Units on a scale
N/A N=49 Interpretation Modification Program for Social Phobia
Social Anxiety Disorder · Social Phobia
Primary: Liebowitz Social Anxiety Scale (LSAS) — 82.0; 77.7; 50.2; 67.6 units on a scale
N/A N=89 Social Phobia Intervention Study of Mannheim
Social Phobia
Primary: Change From Baseline in Social Interaction Anxiety Scale (SIAS) — 43.13; 48.94; 34.85; 33.35 units on a scale — p=<0.05
N/A N=76 Internet Treatment for Social Phobia in Romania
Phobia, Social
Primary: Leibowitz Social Anxiety Scale - Self Report (LSAS-SR) — 78.60; 78.47; 73.69; 43.98 units on a scale — p=<0.01
N/A N=53 Attention, Teleconferencing and Social Anxiety
Social Anxiety Disorder
Primary: Personal Report of Communication Apprehension Questionnaire — 88.06; 87.64; 95.69 score on a scale
N/A N=23 Treating Phobia With Multivoxel Neuro-reinforcement
Phobia
Primary: Change in Amygdala Reactivity — -.691; -.827; -.278 Beta Coefficient
N/A N=90 Treatment of Social Anxiety Disorder and Selective Mutism
Social Anxiety Disorder · Selective Mutism
Primary: Change in Clinical Severity Ratings (CSR) of SAD & SM on the Anxiety Disorders Interview Schedule - Parent Version (ADIS-P) — -1.26; -1.65; -1.51; -1.24 units on a scale…
N/A N=41 Computer-Based Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change in Percent Dwell Time on Threat Faces — 20.7; 27.1 percentage of dwell time on threat faces
N/A N=250 1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety
Social Anxiety
Primary: Liebowitz Social Anxiety Scale — 81.05; 82.74; 64.11; 73.05 score on a scale
Phase 2 N=39 Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
Phobic Disorders · Anxiety · Social Phobia
Primary: Clinical Global Improvement (CGI-S) Scale — 4.167; 3.833 units on a scale
Phase 3 N=224 PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
Social Anxiety Disorder
Primary: Subjective Units of Distress Scale (SUDS) Score — 77.7; 78.2; 62.3; 61.3 score on a scale — p=.5063
Phase 3 N=61 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 7.77; 7.84 units on a scale — p=.267
N/A N=44 Efficacy of Virtual Reality Exposure Therapy Scripts for Social Phobia
Social Anxiety Disorder
Primary: Change From Baseline in the Social Phobia Diagnostic Questionnaire (SPDQ) at Post-treatment — -9.60; -4.46 score on a scale — p=< 0.05
Phase 3 N=40 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
Social Anxiety Disorder
Primary: The Liebowitz Social Anxiety Scale (LSAS) — 41.0; 33.3 units on a scale — p=.015
Phase 2 N=151 A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 22.42; 24.26…
N/A N=54 Telemedicine-Based Virtual Reality Clinic for the Treatment of Phobias
Arachnophobia · Cynophobia · Ophidiophobia
Primary: Phobia Symptom Severity — 2.80; 3.18; 1.51; 1.55 units on a scale
Phase 3 N=29 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
Phobic Disorders
Primary: Acrophobia Questionnaire With Avoidance (AAVQ) — 9.00; 12.38 units on a scale
Phase 4 N=42 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Social Anxiety Disorder · Social Phobia · Alcohol Use Disorder
Primary: Social Anxiety Severity — 87; 93 units on a scale
Phase 2 N=54 Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder
Social Anxiety Disorder
Primary: Social Cooperation — 4.42; 4.69 Ball tosses
Phase 2 N=83 SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Generalized Anxiety Disorder (GAD) · Anxiety, Separation · Phobia, Social
Primary: Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks — -1.7; -2.3 mmHg
N/A N=73 Hormones and Social Anxiety Disorder Treatment
Social Anxiety Disorder
Primary: LSAS-performance Subscale — 34.04; 32.54; 32.05 units on a scale
Phase 2 N=54 fMRI Study Examining Effects of D-cycloserine in Specific Phobia
Phobias
Primary: fMRI Brain Activations During Symptom Provocation — .200; .157; -.013; .036 percent signal change
N/A N=88 Variations of Cognitive Behavior Therapy for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Social Phobia and Anxiety Inventory (SPAI) - Social Phobia Subscale — 131.66; 130.17; 75.47; 103.9 units on a scale
N/A N=45 Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety
Public Speaking · Social Fear
Primary: Number of Participants in Remission (Per Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)) — 21; 20 participants
Phase 3 N=27 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
Generalized Social Phobia
Primary: Clinical Global Impression (Change Version, Also Known as Improvement Version) — 3; 4 participants
N/A N=20 Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
Specific Phobia
Primary: Snake Questionnaire (SNAQ) — 9.6; 9.7 units on a scale
Phase 3 N=22 Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
Social Anxiety Disorder · Performance Anxiety
Primary: VAS-anxiety Immediately After the Impromptu Speech Task — 54.3; 62.6 millimeters (units on a scale) — p=0.056